Skip to main content
Key Specialties
Cardiology Diabetology Endocrinology Gastroenterology Geriatrics and Gerontology Gynecology and Obstetrics Hematology Infectious Disease Internal Medicine Nephrology Neurology Oncology Pediatrics Respiratory Medicine Rheumatology Surgery
Congress Coverage
2024 ACC Congress 2023 ESMO Congress 2023 EASD Congress 2023 ERS Congress 2023 ESC Congress
Clinical Collections
Advances in Alzheimer’s

Keynote webinar | Spotlight on medication adherence

LIVE: Thursday 27th June 2024, 18:00-19:30 (CEST)
Join our expert panel to discover why you need to understand the drivers of non-adherence in your patients, and how you can optimize medication adherence in your clinics to drastically improve patient outcomes.
ADVANCED SEARCH
Log in
Top
Breast Cancer Research and Treatment
Published in: Breast Cancer Research and Treatment 2/2000

01-03-2000

EORTC 10941: A phase II study of liarozole in postmenopausal patients with ‘Chemotherapy-Resistant’ or ‘Potentially Hormone Sensitive’ metastatic breast cancer

Authors: A. Hamilton, J.-A. Roy, L. Beex, M. Piccart, L. Mauriac, R. Coleman, R. Paridaens, G. Hoctin Boes, A. van Vreckem, P. Palmer, J. Klijn

Published in: Breast Cancer Research and Treatment | Issue 2/2000

Login to get access
Metadata
Title
EORTC 10941: A phase II study of liarozole in postmenopausal patients with ‘Chemotherapy-Resistant’ or ‘Potentially Hormone Sensitive’ metastatic breast cancer
Authors
A. Hamilton
J.-A. Roy
L. Beex
M. Piccart
L. Mauriac
R. Coleman
R. Paridaens
G. Hoctin Boes
A. van Vreckem
P. Palmer
J. Klijn
Publication date
01-03-2000
Publisher
Kluwer Academic Publishers
Published in
Breast Cancer Research and Treatment / Issue 2/2000
Print ISSN: 0167-6806
Electronic ISSN: 1573-7217
DOI
https://doi.org/10.1023/A:1006398518037

Other articles of this Issue 2/2000

Breast Cancer Research and Treatment 2/2000 Go to the issue

OriginalPaper

Polyamine profiles in tumor, normal tissue of the homologous breast, blood, and urine of breast cancer sufferers

OriginalPaper

Cellular responses of mammary carcinomas to aromatase inhibitors: Effects of vorozole

OriginalPaper

RT-PCR amplification of CK19 mRNA in the blood of breast cancer patients: correlation with established prognostic parameters

OriginalPaper

T cell suppression as a mechanism for tolerance to MUC1 antigen in MUC1 transgenic mice

OriginalPaper

Eye problems in breast cancer patients treated with tamoxifen

OriginalPaper

Anti-tumor immunity induced by Interleukin-12 gene therapy in a metastatic model of breast cancer is mediated by natural killer cells
Webinar | 19-02-2024 | 17:30 (CET)

Keynote webinar | Spotlight on antibody–drug conjugates in cancer

Watch now

Antibody–drug conjugates (ADCs) are novel agents that have shown promise across multiple tumor types. Explore the current landscape of ADCs in breast and lung cancer with our experts, and gain insights into the mechanism of action, key clinical trials data, existing challenges, and future directions.

Dr. Véronique Diéras
Prof. Fabrice Barlesi
Developed by: Springer Medicine
Image Credits